KL-6与IL-18水平在系统性硬化症相关间质性肺病患者中与呼吸功能检查及HRCT评估的ILD范围呈负相关
横断面研究纳入74例符合2013年ACR/EULAR标准的系统性硬化症患者,其中28例(38%)存在间质性肺病。血清KL-6和IL-18在SSc-ILD患者中升高,且与%FVC和%DLCO呈负相关,与HRCT半定量ILD范围分级呈正相关。
要点
- SSc-ILD患者血清KL-6和IL-18水平较无ILD患者升高(p=0.003和p=0.04)。
- KL-6与%FVC(β=-0.25)和%DLCO(β=-0.28)呈负相关,IL-18与%FVC(β=-0.38)和%DLCO(β=-0.27)呈负相关。
- KL-6和IL-18可区分HRCT半定量ILD范围1级与2级(p=0.028和p=0.022)。
核心结论
- 血清KL-6和IL-18在SSc-ILD患者中升高,与半定量CT分级评估的ILD严重程度呈正相关,与肺功能参数呈负相关。
- 血清KL-6和IL-18可能是筛查和评估SSc-ILD的临床有用生物标志物。
研究设计与样本
- 横断面研究,纳入74例符合2013年ACR/EULAR标准的系统性硬化症患者,根据疾病病程和肺部受累(是否存在ILD)进行分类。
- 所有患者基线时接受胸部HRCT和肺功能检查,采用定量ELISA(固相夹心法)测定血清KL-6、IL-18和IL-18BP浓度。
- HRCT采用半定量ILD范围分级(1级0-20%;2级>20%),广泛病变定义为HRCT肺受累>20%且FVC<预计值70%,局限肺受累定义为HRCT ILD受累≤20%且FVC≥预计值70%。
主要发现
- 74例患者中27%为男性,诊断时平均年龄57.5±15岁,诊断后平均时间7.67±8年,28例(38%)存在ILD,64%患者HRCT ILD范围<20%。
- SSc-ILD患者血清KL-6和IL-18水平较无ILD患者升高(p=0.003和p=0.04),调整年龄和性别后该结果仍保留。
- KL-6与%FVC(β=-0.25,p=0.037)和%DLCO(β=-0.28,p=0.02)呈负相关,IL-18与%FVC(β=-0.38,p=0.001)和%DLCO(β=-0.27,p=0.03)呈负相关。
- 血清KL-6和IL-18可区分HRCT半定量ILD范围1级与2级(p=0.028和p=0.022),HRCT半定量ILD分级与KL-6(p=0.01)和IL-18(p=0.03)显著成比例。
- 广泛肺病变与KL-6呈正相关(β=0.42,p=0.007),但与IL-18无相关性。
关键数值与推荐
- SSc-ILD患者血清KL-6和IL-18水平较无ILD患者升高(p=0.003和p=0.04)。
- KL-6与%FVC(β=-0.25,p=0.037)和%DLCO(β=-0.28,p=0.02)呈负相关。
- IL-18与%FVC(β=-0.38,p=0.001)和%DLCO(β=-0.27,p=0.03)呈负相关。
- KL-6和IL-18区分HRCT半定量ILD范围1级与2级(p=0.028和p=0.022)。
- 广泛肺病变与KL-6正相关(β=0.42,p=0.007),与IL-18无相关性。
临床怎么用
- 血清KL-6和IL-18可能是筛查和评估SSc-ILD的临床有用生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Serum biomarkers have been suggested as indicators for pulmonary damage with clinical value in the diagnosis and prognosis of SSc-ILD. OBJECTIVES: To investigate the role of serum biomarkers (Krebs von den Lungen-6 KL-6, IL-18 and IL-18BP) as a potential biomarker reflecting the severity of SSc-ILD as assessed through high-resolution computed tomography (HRCT) and pulmonary function tests (PFT), including forced vital capacity (%FVC) and diffusing capacity of the lung for carbon monoxide (%DLCO). METHODS: A cross-sectional study including patients with SSc fulfilling the 2013 ACR/EULAR criteria was performed. Patients were classified according to disease duration and pulmonary involvement (presence of ILD). All SSc patients underwent chest HRCT scans and pulmonary function test at baseline. Serum concentration of KL-6, IL8 and IL18BP were determined using the quantitative ELISA technique, sandwich type (solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay), with kits from MyBiosource for KL-6 and from Invitrogen for IL18 and IL18BP. A semiquantitative grade of ILD extent was evaluated through HRCT scan (grade 1, 0-20%; grade 2, >20%). Extensive disease was defined as >20% lung involvement on HRCT, and FVC <70% predicted and limited lung involvement as ≤20% ILD involvement on HRCT, and an FVC ≥70% predicted. RESULTS: 74 patients were included, 27% were male. The mean age at diagnosis was 57.5±15 years and the mean time since diagnosis was 7.67±8 years. 28 patients had ILD (38%). 64% of patients had <20% ILD extent classified through HRCT scan. SSc-ILD patients had elevated serum KL-6 and IL-18 levels compared to patients without ILD (p=0.003 and p=0.04), and those findings were preserved after adjusting for age and sex. Negative correlation between KL-6 levels and%FVC (β=-0.25, p 0.037) and% DLCO (β=-0.28, p 0.02) and between IL-18 levels and%FVC (β=-0.38, p 0.001) and%DLCO (β=-0.27, p 0.03) were found. Serum KL-6 and IL-18 levels successfully differentiated grades 1 and 2 of the semiquantitative grades of ILD extent (p = 0.028 and p = 0.022). Semiquantitative grades of ILD on the HRCT scan were significantly proportional to the KL-6 (p = 0.01) and IL-18 (p = 0.03). A positive correlation between extensive lung disease and KL-6 (β=0.42, p = 0.007) but not with IL-18 was found. CONCLUSIONS: Serum KL-6 levels and IL-18 were increased in patients with SSc-ILD and showed a positive correlation with ILD severity as measured using a semiquantitative CT grading scale and negative correlation with PFT parameters. Serum KL-6 and IL-18 could be a clinically useful biomarker in screening and evaluating SSc-ILD.
引用
- Sieiro Santos C, Antolín SC, Lorenzo JC, et al. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD). Semin Arthritis Rheum. 2024. PMID: 38290372. doi:10.1016/j.semarthrit.2024.152366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。